Protecting Youth Mental Health: The US Surgeon General’s Advisory
The challenges today’s generation of young people face are unprecedented and uniquely hard to navigate. And the effect these challenges have had on their mental health is devastating. Recent national surveys of young people have shown alarming increases in the prevalence of certain mental health challenges. We know that mental health is shaped by many…
Read MoreCHADD’s Statement at the Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder
Presentation to the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the US Food and Drug Administration Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder Presented by Robert Cattoi, CHADD Chief Executive Officer Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) appreciates the opportunity…
Read MoreUPDATE: CARES Act And Protecting Educational Rights of Students With ADHD
CHADD is pleased to report that Secretary of Education Betsy DeVos will not seek changes to the central tenets of the Individuals with Disabilities Education Act (IDEA) in response to the novel coronavirus pandemic. In her report, the Secretary is “not requesting waiver authority for any of the core tenets of the IDEA or Section…
Read MoreCARES Act And Protecting Educational Rights of Students With ADHD
Read the update to this post. Dear Parents, The Coronavirus Aid, Relief, and Economic Security (CARES) Act, PL 116-136, directs Secretary of Education Betsy DeVos to report back to Congress no later than April 26, 2020, on any waivers needed under the Individuals with Disabilities Education Act (IDEA) and the Rehabilitation Act of 1973 (Section…
Read MoreQ&A: Providing Services to Children with ADHD & Disabilities During the COVID-19 Outbreak
The CHADD Public Policy Committee is sharing the document Questions and Answers on Providing Services to Children with Disabilities during the Coronavirus Disease 2019 Outbreak. This document addresses questions on IDEA and Section 504 educational plans, along with meeting the needs of children with disabilities who may also be affected by COVID-19. The Centers for…
Read MoreCHADD Responds to FDA Request for Comments on ADHD Medications
The US Food and Drug Administration recently asked for comments on making stimulant medications more difficult to abuse and how those changes could affect the millions of people who include medication in their ADHD treatment plans. The Federal Register notice states that stimulant medications can be open to abuse but that reformulating them can potentially…
Read MoreCharter Schools: Discipline and Implications for Students with ADHD
At eight years old, Michael was diagnosed with ADHD. The traditional city school he attended declined to evaluate him to determine eligibility for special education and related services because his grades were above average. Instead, the school provided Michael with minimal accommodations through a 504 plan. As the years progressed, Michael’s grades began to decline,…
Read MoreNew Research Suggests Untreated ADHD Reduces Life Expectancy
CHADD and Russell A. Barkley, Ph.D., Partner Announce New Findings Lanham, Md. (Jan. 8, 2019)— The message is clear. Treatment for attention-deficit/hyperactivity disorder (ADHD), along with the related health risks it poses, has the possibility of adding an average of nine to 13 years to the lifespan of children and adults diagnosed with ADHD.…
Read MoreCHADD Position Statement on Controlled Substances Measures
CHADD has become aware of state and local policies, including legislation and regulations, intended to address the misuse of opioids, but which may have unintended consequences for children and adults prescribed FDA-approved medications to treat attention deficit hyperactivity disorder (ADHD). Read the full statement.
Read MoreCHADD’s Position on Patient Access to ADHD Medications
Medication Access Principles: CHADD ascribes to the following principles regarding access to medications indicated to treat attention deficit / hyperactivity disorder (ADHD). Medication is recognized by the scientific community as a primary treatment to effectively reduce the core symptoms of ADHD.[1] Given the stigma associated with ADHD and common misconceptions about treating the disorder, individuals…
Read MoreAmerican Health Care Act
The House of Representatives had been preparing to vote on the American Health Care Act (AHCA), which would repeal significant portions of the Affordable Care Act (ACA or “Obamacare”) and replace them with alternative coverage policies. At this time, the House is not moving forward with a vote on the AHCA. Read our full report.
Read MoreHealth Insurance Coverage and ADHD
In September 2016, CHADD conducted a survey about health insurance coverage and attention deficit hyperactivity disorder (ADHD) in the United States. More than 1500 people from all 50 states and Washington, D.C. took part in the online survey and answered 15 anonymous questions about their personal experiences seeking access to services and medications for their,…
Read More